Literature DB >> 16732705

Pharmacotherapy of allergic eye disease.

Bita Manzouri1, Thomas H Flynn, Frank Larkin, Santa J Ono, Richard Wyse.   

Abstract

Allergic eye disease is a term that refers to a number of disease processes that affect about one-fifth of the world's population. Although the more advanced forms of the disease can be sight threatening, the most disabling effects are due to the clinical manifestations, and hence quality of life, with some patients having seasonal exacerbations of their symptoms, whereas others have symptoms that are present throughout the year. Recent increased understanding of the cellular and mediator mechanisms that are involved in the various disease manifestations has greatly facilitated the development of more effective treatment options. Newer topical medications are being used that have multiple actions, such as an antihistaminic effect coupled with mast-cell stabilisation, and which require reduced daily dosing due to their longer duration of action. With greater research into newer therapies and more effective modes of delivery, improved healthcare outcomes with a lower economic burden will be achieved for patients with allergic eye disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732705     DOI: 10.1517/14656566.7.9.1191

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.

Authors:  Gyan P Mishra; Viral Tamboli; Jwala Jwala; Ashim K Mitra
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2011-01

Review 2.  Ocular redness - I: Etiology, pathogenesis, and assessment of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Sonia Anchouche; Ann Yung; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-16       Impact factor: 6.268

3.  Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis.

Authors:  Navdeep Dehar; Anita Gupta; Gursatinder Singh
Journal:  Int J Appl Basic Med Res       Date:  2012-01

4.  A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model.

Authors:  Stacey Ackerman; Francis D'Ambrosio; Jack V Greiner; Linda Villanueva; Joseph B Ciolino; David A Hollander
Journal:  J Asthma Allergy       Date:  2013-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.